Ms. Bresch faced large backlash in the past few weeks over the more than 500 percent price hike on Mylan’s life-saving EpiPen medication.
She first made Fortune‘s MPW list in 2012 right after she stepped into the role of CEO at Mylan. While Ms. Bresch ranked No. 47 on the 50-person list in 2012, this year she sits at No. 23, down one spot from her 2015 rank.
Fortune said it chose to keep Ms. Bresch on the list this year because the list simply represents the most powerful women in business and rankings are not affected by how each female wields that power. Fortune suggests that the EpiPen controversy actually indicates just how powerful Ms. Bresch is within the business world and drug industry.
To view the complete “Most Powerful Women” list, click here.
More articles on supply chain:
Device companies struggle to meet UDI requirements: 4 things to know
EpiPen prescriptions spike in August despite pricing controversy
5 quotes from Sen. Manchin on his CEO daughter, Mylan, and high drug prices
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
